Acutaas Chemicals Ltd.
NSE: ACUTAASAcutaas Chemicals Ltd.: A 30-second snapshot
Acutaas Chemicals trades at ₹3,297.7, up 180.23% over the past year and 27.12% over the past three months, sitting 11.83% below its 52-week high and almost exactly at its 50-day SMA (₹3,296.53) while well above its 200-day SMA (₹2,326.69). Trailing PE of 94.57 is the highest among 6 tracked pharma-sector companies compared, even as Q1 net profit reportedly rose 70% YoY. Mean analyst rating stands at 2 across 10 analysts (1-5 scale, lower = more constructive).
P/E
94.6
Forward P/E
46.5
ROE
—
Debt / Equity
2.08
Profit Margin
+26.4%
Div. Yield
+0.1%
5Y ROE > 15%
0/5
5Y FCF > 0
0/5
Quality
56/100
News
8 headlines · 3 positive · 0 negative
Buy Acutaas Chemicals Ltd For Target Rs.3,790 - Prabhudas Liladhar Capital Ltd - Investment Guru
Investment Guru
Acutaas Chemicals Q1 Results: Net profit rises 70% YoY - scanx.trade
scanx.trade
Acutaas Chemicals Q1 Results: Multibagger stock falls 6% despite strong Q1, guidance held - CNBC TV18
CNBC TV18
Acutaas Chemicals promotes Anurag Shukla as General Manager Operations - scanx.trade
scanx.trade
Acutaas Chemicals Ltd Revenue Breakdown – NSE:ACUTAAS - TradingView
TradingView
Recent context
- ·Q1 net profit reportedly rose 70% YoY with guidance held, yet the stock fell 6% on the results day, per a July 24 CNBC TV18 headline.
- ·Prabhudas Liladhar Capital issued a note on Acutaas Chemicals on July 28 rating it 'Buy' with a stated target of ₹3,790, per a syndicated headline referencing the note.
- ·The company promoted Anurag Shukla to General Manager, Operations, per a July 2 report.
Strengths
- +5-year revenue growth of 59.1% and earnings growth of 67.1%, with a current profit margin of 26.42%.
- +Price trades above both its 50-day SMA (₹3,296.53) and 200-day SMA (₹2,326.69), up 180.23% over the trailing year.
- +Composite qualityScore of 57 ranks 1st of 6 sector companies compared (vs 44, 28, 4, 37, 56 for peers).
- +News flow over the last period skews non-negative: 3 positive, 5 neutral, 0 negative across 8 tracked articles, including a reported 70% YoY Q1 net profit rise.
Weaknesses
- −Persistence data shows 0 years of ROE above 15% and 0 FCF-positive years, with a consistencyScore of 35/100, despite the recent profit-margin and earnings-growth figures.
- −Debt-to-equity of 2.081 on a rising trend, alongside zero FCF-positive years in the persistence record.
- −Trailing PE of 94.57 is the highest of the 6 sector companies compared (PE rank 6 of 6); forward PE of 46.50 still exceeds most listed peers, which range 28.7x-75.1x.
- −ROE is not available in the current data pull, and priceChange1Y is unavailable for all 5 listed sector peers, limiting direct comparison on those two metrics.
Open questions
- ?Does the composite qualityScore ranking (1st of 6 sector peers) reconcile with the persistence record showing zero years of ROE above 15% and zero FCF-positive years, or is the composite score weighting different factors than raw multi-year profitability?
- ?What is driving the rising debt-to-equity trend (currently 2.081), and how does it relate to the company's stated capex or growth-financing plans?
- ?What specifically drove the stock down 6% on the Q1 results day despite a reported 70% YoY profit rise and held guidance?
- ?How does the gap between trailing PE (94.57) and forward PE (46.50) compare with the sustainability of the reported 59.1%/67.1% revenue and earnings growth rates?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ACUTAAS | Acutaas Chemicals Ltd.You're viewing | 94.6 | — | 57 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 75.1 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.3 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.7 | +8.8% | 4 |
Technical state
Current price
₹3,297.70
SMA 50
₹3,296.53
SMA 200
₹2,326.69
RSI (14)
44.1 (neutral)
From 52w high
-11.8%
1Y return
+180.2%
3M return
+27.1%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highPersistence metrics show roeYearsAbove15 = 0 and fcfPositiveYears = 0 with a consistencyScore of 35/100, meaning the reported profit margin of 26.42% and 5-year earnings growth of 67.1% are not corroborated by a multi-year record of sustained ROE above 15% or positive free cash flow.
- highDebt-to-equity of 2.081 with a rising debt trend, combined with zero FCF-positive years in the persistence record; this leverage profile sits well above the general pharma benchmark and would amplify strain if earnings growth slows.
- mediumTrailing PE of 94.57 is the highest among the 6 sector companies compared (ranked 6th of 6 on PE); peer PEs range 28.7x-75.1x. Forward PE of 46.50 still implies a materially higher multiple than most listed peers.
- lowROE is unavailable (null) in the current fundamental data pull, and priceChange1Y is unavailable for all 5 listed sector peers, limiting like-for-like comparison on those two metrics.
Cross-section contradictions
- The composite qualityScore ranks the stock 1st of 6 tracked pharma-sector companies (57 vs 44/28/4/37/56), yet the persistence data underlying that same fundamental profile shows roeYearsAbove15 = 0, fcfPositiveYears = 0, and a consistencyScore of only 35/100 - the sector-relative quality ranking and the multi-year consistency record point in different directions.
- Price has risen 180.23% over the past year and sits within 11.83% of its 52-week high, while the persistence record shows zero FCF-positive years and a rising debt trend - price action and multi-year cash-generation data are moving in opposite directions.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 12 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 30 Jul 2026 · rotates through NIFTY 500 every ~5 days